The Top 5 Biosimilars Articles for the Week of June 24

June 28, 2019

The Center for Biosimilars® recaps the top stories for the week of June 24, 2019.

Transcript

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 24.

Number 5: Alexion says that the FDA will give priority review to its long-acting C5 complement inhibitor. The drug offers less frequent administration than Soliris, which faces upcoming biosimilar competition.

Number 4: A UK court has denied Pfizer an Arrow declaration in its pursuit to launch biosimilar bevacizumab.

Number 3: At the ACI 10th Summit on Biosimilars, experts explained the circumstances under which biosimilar developers might challenge patents via the International Trade Commission.

Number 2: Henlius says that the European Medicines Agency will review the company’s trastuzumab biosimilar.

Number 1: Drug maker AbbVie announced that it has reached a transaction agreement under which it will acquire Allergan.

Finally, last week, our e-newsletter asked whether you think the United States is catching up with the European Union in its effort to bring biosimilars to patients.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.